Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2971 participants
OBSERVATIONAL
2002-02-28
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis
NCT00076726
Remicade Safety Line (Study P03236)(COMPLETED)
NCT00748826
Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)
NCT00818168
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
NCT04990258
A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
NCT00380796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients in infliximab clinical studies
All patients enrolled in selected Centocor sponsored infliximab clinical studies.
Infliximab (Remicade)
This is an non-interventional study. Participants took the study product as part of their medical routine.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infliximab (Remicade)
This is an non-interventional study. Participants took the study product as part of their medical routine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centocor BV
INDUSTRY
Centocor, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Centocor, Inc. Clinical Trial
Role: STUDY_DIRECTOR
Centocor, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Huntsville, Alabama, United States
Montgomery, Alabama, United States
Paradise Valley, Arizona, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Anaheim, California, United States
Fresno, California, United States
Irvine, California, United States
Los Angeles, California, United States
Madera, California, United States
Orange, California, United States
Pasadena, California, United States
Rancho Mirage, California, United States
San Diego, California, United States
Santa Monica, California, United States
Stanford, California, United States
Torrance, California, United States
Denver, Colorado, United States
Hamden, Connecticut, United States
Hartford, Connecticut, United States
New Haven, Connecticut, United States
Waterbury, Connecticut, United States
Aventura, Florida, United States
Largo, Florida, United States
Ocala, Florida, United States
Orlando, Florida, United States
Palm Harbor, Florida, United States
Sarasota, Florida, United States
Tampa, Florida, United States
Alpharetta, Georgia, United States
Atlanta, Georgia, United States
Marietta, Georgia, United States
Coeur d'Alene, Idaho, United States
Chicago, Illinois, United States
Evanston, Illinois, United States
Gurnee, Illinois, United States
Maywood, Illinois, United States
Normal, Illinois, United States
Rockford, Illinois, United States
Springfield, Illinois, United States
Indianapolis, Indiana, United States
Iowa City, Iowa, United States
Overland Park, Kansas, United States
Wichita, Kansas, United States
Louisville, Kentucky, United States
Portland, Maine, United States
Baltimore, Maryland, United States
Greenbelt, Maryland, United States
Wheaton, Maryland, United States
Andover, Massachusetts, United States
Boston, Massachusetts, United States
Worcester, Massachusetts, United States
Ann Arbor, Michigan, United States
Detroti, Michigan, United States
East Lansing, Michigan, United States
Grand Rapids, Michigan, United States
Edina, Minnesota, United States
Fridley, Minnesota, United States
Jackson, Mississippi, United States
St Louis, Missouri, United States
Lincoln, Nebraska, United States
Reno, Nevada, United States
Voorhees Township, New Jersey, United States
Manhasset, New York, United States
New York, New York, United States
Rochester, New York, United States
Charlotte, North Carolina, United States
Durham, North Carolina, United States
Raleigh, North Carolina, United States
Wilmington, North Carolina, United States
Winston-Salem, North Carolina, United States
Akron, Ohio, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Oklahoma City, Oklahoma, United States
Lake Oswego, Oregon, United States
Portland, Oregon, United States
Bethlehem, Pennsylvania, United States
Lancaster, Pennsylvania, United States
Norristown, Pennsylvania, United States
Philadelphia Pennsylvan, Pennsylvania, United States
West Reading, Pennsylvania, United States
Willow Grove, Pennsylvania, United States
North Charleston, South Carolina, United States
Goodlettsville, Tennessee, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
Lubbock, Texas, United States
San Antonio, Texas, United States
Burlington, Vermont, United States
Salem, Virginia, United States
Bellevue, Washington, United States
Kirkland, Washington, United States
Seattle, Washington, United States
Spokane, Washington, United States
Milwaukee, Wisconsin, United States
Buenos Aires, , Argentina
Córdoba, , Argentina
Cp, , Argentina
Rosario, , Argentina
San Miguel de Tucumán, , Argentina
Graz, , Austria
Innsbruck, , Austria
Vienna, , Austria
Brussels, , Belgium
Diepenbeek, , Belgium
Edegem, , Belgium
Genk, , Belgium
Ghent, , Belgium
Leuven, , Belgium
Liège, , Belgium
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Richmond, British Columbia, Canada
Vancouver, British Columbia, Canada
Winnipeg, Manitoba, Canada
Moncton, New Brunswick, Canada
St. John's, Newfoundland and Labrador, Canada
Halifax, Nova Scotia, Canada
Hamilton, Ontario, Canada
Kitchener, Ontario, Canada
London, Ontario, Canada
Markham, Ontario, Canada
Newmarket, Ontario, Canada
North Bay, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Waterloo, Ontario, Canada
Montreal, Quebec, Canada
Québec, Quebec, Canada
Sainte-Foy, Quebec, Canada
Sherbrooke, Quebec, Canada
Ste-Foy, Quebec, Canada
Halifax, , Canada
Hamilton Ontario, , Canada
Montreal, , Canada
Saskatoon, , Canada
Aarhus, , Denmark
Hellerup, , Denmark
Hvidovre, , Denmark
København NV, , Denmark
Odense, , Denmark
Helsinki, , Finland
Hus, , Finland
Jyväskylä, , Finland
Pikonlinna, , Finland
Créteil, , France
Montpellier, , France
Nantes, , France
Nice, , France
Paris, , France
Pierre-Bénite, , France
Poitiers, , France
Berlin, , Germany
Bochum, , Germany
Cologne, , Germany
Dresden, , Germany
Erlangen, , Germany
Frankfurt, , Germany
Hamburg, , Germany
Leipzig, , Germany
Mainz, , Germany
Münster, , Germany
Oldenburg, , Germany
Würzburg, , Germany
Wÿrzburg, , Germany
Budapest, , Hungary
Debrecen, , Hungary
Dublin, , Ireland
Haifa, , Israel
Tel Aviv, , Israel
Amsterdam-Zuidoost, , Netherlands
Maastricht, , Netherlands
Rotterdam, , Netherlands
Utrecht, , Netherlands
Oslo, , Norway
Bialystok, , Poland
Lublin, , Poland
Szczecin, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Włoszczowa, , Poland
Barcelona, , Spain
Buenos Aires, , Spain
Córdoba, , Spain
Federal, , Spain
Madrid, , Spain
Gothenburg, , Sweden
Geneva, , Switzerland
Zurich, , Switzerland
Bath, , United Kingdom
Birmingham, , United Kingdom
Cambridge, , United Kingdom
Cannock, , United Kingdom
Leeds, , United Kingdom
Liverpool, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Newcastle upon Tyne, , United Kingdom
Norwich, , United Kingdom
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Study results from the long term safety follow-up of REMICADE (RESULTS)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C0168T45
Identifier Type: OTHER
Identifier Source: secondary_id
CR004780
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.